查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1991393

全球抗癌藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Oncology Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計抗癌藥物市場規模將從 2025 年的 2,605.4 億美元成長到 2034 年的 7,064.1 億美元，2026 年至 2034 年的複合年成長率為 11.72%。

由於癌症發病率上升和醫學研究的進步，全球抗癌藥物市場正經歷顯著成長。抗癌藥物透過靶向癌細胞或抑制其生長來治療各種類型的癌症。製藥公司和研究機構不斷開發創新治療方法，以提高患者的存活率和治療效果。

多種因素正在推動抗癌藥物市場的成長。全球癌症患者數量的不斷增加以及人們對早期診斷意識的提高，都推動了對有效治療方法的需求。生物技術、免疫療法和標靶治療的進步拓寬了治療選擇，使醫療專業人員能夠制定個人化的癌症治療方案。

抗癌藥物市場前景依然光明，因為研究不斷湧現新的治療方法。正在進行的臨床試驗和精準醫療的進步有望進一步改善治療效果。隨著醫療系統擴大先進癌症治療的覆蓋範圍，抗癌藥物市場預計將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球抗癌藥物市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 細胞毒性藥物
  • 標靶治療藥物
  • 荷爾蒙藥物
  • 其他

第5章 全球抗癌藥物市場：依療法分類

  • 市場分析、洞察與預測
  • 化療
  • 標靶治療
  • 免疫療法

第6章 全球抗癌藥物市場：依適應症分類

  • 市場分析、洞察與預測
  • 肺癌
  • 胃癌
  • 結腸癌
  • 乳癌
  • 攝護腺癌
  • 其他

第7章 全球抗癌藥物市場：以劑型分類

  • 市場分析、洞察與預測
  • 固體的
  • 液體
  • 注射藥物

第8章 全球抗癌藥物市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 全球抗癌藥物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc
    • Novartis AG
    • Pfizer Inc
    • Bristol Myers Squibb Company
    • GlaxoSmithKline Plc
    • Eli Lilly And Company
    • AstraZeneca
    • Sanofi
    • Bayer AG
    • Merck & Co. Inc
簡介目錄
Product Code: VMR11213665

The Oncology Drugs Market size is expected to reach USD 706.41 Billion in 2034 from USD 260.54 Billion (2025) growing at a CAGR of 11.72% during 2026-2034.

The global oncology drugs market has experienced significant growth due to the increasing prevalence of cancer and advancements in medical research. Oncology drugs are used to treat various types of cancer by targeting cancer cells or slowing their growth. Pharmaceutical companies and research institutions continue to develop innovative therapies to improve survival rates and treatment outcomes for patients.

Several factors are driving the growth of the oncology drugs market. Rising global cancer cases and growing awareness about early diagnosis have increased demand for effective treatments. Advances in biotechnology, immunotherapy, and targeted therapies have expanded treatment options, allowing healthcare providers to personalize cancer care.

The future outlook for the oncology drugs market remains promising as research continues to produce new treatment approaches. Ongoing clinical trials and advances in precision medicine may further improve treatment effectiveness. As healthcare systems expand access to advanced cancer therapies, the oncology drugs market is expected to grow steadily.

MARKET SEGMENTATION

By Drug Class

  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others

By Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others

By Dosage Form

  • Solid
  • Liquid
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, AbbVie Inc, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, Bayer AG, Merck Co Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Cytotoxic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Targeted Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Hormonal Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapy
  • 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Indication
  • 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Dosage Form
  • 7.2. Solid Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONCOLOGY DRUGS MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Drug Class
    • 9.2.2 By Therapy
    • 9.2.3 By Indication
    • 9.2.4 By Dosage Form
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Drug Class
    • 9.3.2 By Therapy
    • 9.3.3 By Indication
    • 9.3.4 By Dosage Form
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Drug Class
    • 9.4.2 By Therapy
    • 9.4.3 By Indication
    • 9.4.4 By Dosage Form
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Drug Class
    • 9.5.2 By Therapy
    • 9.5.3 By Indication
    • 9.5.4 By Dosage Form
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Drug Class
    • 9.6.2 By Therapy
    • 9.6.3 By Indication
    • 9.6.4 By Dosage Form
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONCOLOGY DRUGS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 F. Hoffmann-La Roche Ltd
    • 11.2.2 AbbVie Inc
    • 11.2.3 Novartis AG
    • 11.2.4 Pfizer Inc
    • 11.2.5 Bristol Myers Squibb Company
    • 11.2.6 GlaxoSmithKline Plc
    • 11.2.7 Eli Lilly And Company
    • 11.2.8 AstraZeneca
    • 11.2.9 Sanofi
    • 11.2.10 Bayer AG
    • 11.2.11 Merck & Co. Inc